Search the Newsreel

Earnings Flash (MXL) MaxLinear, Inc. Posts Q2 Adjusted EPS $0.35 per Share, vs. FactSet Est of $0.33

MaxLinear, Inc. (MXL) reported adjusted earnings per share of $0.35 for Q2, surpassing FactSet's estimate of $0.33. The company also announced a rise in Q2 adjusted earnings and revenue, alongside providing a Q3 revenue outlook. MaxLinear's stock price saw an increase of 5.12% in …

Lineage reveals ways it’s aiming to control foul odor at burned-out Boyle Heights food warehouse

Lineage Logistics has detailed its odor-mitigation plans for the burned-out cold-storage warehouse in Boyle Heights, where rotting food has generated numerous odor complaints and violations. The company's measures include odor-control sprays, neutralizer application, building wrapping, carbon filters, and strict waste transportation protocols to address …

MaxLinear (MXL) Stock Draws Bullish Targets Ahead Of Earnings

MaxLinear (MXL) stock is drawing bullish attention and higher price targets from analysts ahead of its Q2 2026 earnings report, despite recent volatility and negative net margins. Stifel and Wells Fargo have both raised their price targets, impressed by MaxLinear's growth prospects in data …

Lineage submits plan for Boyle Heights odor controls

Lineage Logistics submitted a plan to the South Coast Air Quality Management District (AQMD) detailing additional odor-control measures for its fire-damaged cold-storage warehouse in Boyle Heights. This comes after over 900 odor complaints and six violation notices due to rotting food. Local officials and …

AXR vs. MLP: Which Land-Focused Real Estate Stock Is the Better Buy?

This article compares two land-focused real estate companies, AMREP (AXR) and Maui Land & Pineapple Company (MLP), to determine which offers a better investment opportunity. While both companies hold significant land assets, AXR focuses on residential development in New Mexico, supported by a strong …

AMRX: Amneal Pharmaceuticals Inc - Ordinary Shares - Class A Latest Stock Price, Analysis, News and Trading Ideas

This article provides current stock information for Amneal Pharmaceuticals Inc (AMRX), including its latest stock price, market capitalization, volume, and key financial ratios. It also highlights recent news from Zacks indicating AMRX as a strong growth and momentum stock, along with discussions about other …

Maui Land & Pineapple (NYSE:MLP) Stock Price Crosses Below 200 Day Moving Average - What's Next?

Price to earnings forward of Maui Land & Pineapple Company, Inc. – NYSE:MLP

This article briefly presents the "Price to earnings forward" metric for Maui Land & Pineapple Company, Inc. (NYSE: MLP). It is a financial data point displayed within the TradingView platform, noting no current trades and a closed market for the stock. The content is …

Deadline for Lineage to address odor from Boyle Heights warehouse is here

Lineage Logistics faces a deadline today to resolve the foul odor emanating from its Boyle Heights warehouse, which caught fire nearly a month ago. State regulators have received almost 1,000 complaints, with residents reporting headaches and nausea due to the smell of over 85 …

Maxlinear Inc expected to post earnings of 33 cents a share - Earnings Preview

Maxlinear Inc is projected to report earnings of 33 cents per share, according to a recent earnings preview. This information is provided by Refinitiv and is available for further analysis on TradingView's Supercharts.

MaxLinear Jumps 8.2% After Wells Fargo Maintains Equal-Weight

MaxLinear (MXL) surged 8.2% after Wells Fargo significantly raised its price target for the semiconductor company by 78.6%, from $42 to $75, while maintaining an "Equal-Weight" rating. Although the stock closed at $77.72, above the new target, the substantial increase in the price target …

MaxLinear (MXL) Q2 2026 Preview: EPS Est. $0.33, Reports July 23

Wall Street anticipates a significant recovery for MaxLinear (MXL) in its Q2 2026 earnings report on July 23rd, with an estimated EPS of $0.33 and revenue of $164.7 million. This forecast represents a dramatic improvement from the previous year, with EPS expected to increase …

MaxLinear (MXL) Leads Upcoming Earnings with Top Quant Rating

MaxLinear (MXL) has secured the highest quant rating of 4.99 alongside Intel Corporation (INTC) as earnings season approaches, indicating strong investor confidence despite a moderate GF Score™ of 57 and significant insider selling. The company, a key player in broadband communications semiconductors, shows financial …

(MXL) Price Dynamics and Execution-Aware Positioning

Maxlinear Inc (NYSE: MXL) is showing weak near and mid-term sentiment, potentially challenging a long-term positive outlook, with support currently being tested. The article details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each tailored to different risk profiles and holding periods, and …

(MLP) Risk Channels and Responsive Allocation

The article provides a detailed analysis of Maui Land & Pineapple Company Inc. (NYSE: MLP), highlighting divergent sentiment readings and offering institutional-grade trading strategies. It outlines specific entry/target/stop-loss zones for position, momentum breakout, and risk hedging strategies, emphasizing the strong risk-reward setup. The analysis …

MaxLinear (MXL) Stock Forecast & Analyst Ratings

This article provides a stock forecast and analyst ratings for MaxLinear (MXL). While the content itself is missing, the title indicates a focus on the company's financial outlook and expert opinions.

LCTX Q1 2026 Earnings: EPS Misses Estimates as Development-Stage Biotech Reports No Revenue - Buyback Announcement Report

How First-Generic OMNIPAQUE Rivals At Amneal Pharmaceuticals (AMRX) Have Changed Its Investment Story

Amneal Pharmaceuticals recently received FDA approval for additional strengths and vial sizes of its iohexol radiographic contrast injection, becoming the first generic version referencing OMNIPAQUE across these presentations. This expands Amneal's reach in a US$706 million market and supports its strategy of leaning on …

UBS Raises Price Target on Lineage to $45 From $35, Maintains Neutral Rating

UBS has increased its price target for Lineage Logistics from $35 to $45, while retaining a Neutral rating on the stock. This adjustment reflects a more optimistic valuation of the company's future stock performance.

'You can't even breathe': Regulators cite Lineage over putrid odor of rotting meat spreading in Boyle Heights

Regulators have issued multiple violations to Lineage Logistics due to the putrid odor of rotting meat emanating from its fire-damaged cold storage facility in Boyle Heights. Residents have filed over 900 complaints, describing the smell as unbearable and leading to health issues and pest …

A Look at MaxLinear Inc (MXL) After 3.4% Decline -- GF Value $17

MaxLinear Inc (MXL) shares dropped 3.4%, extending a significant decline over the past week and month. The stock is considered significantly overvalued with a GF Value of $17.93 against a current price of $71.84, showing a 300.7% overvaluation. Insider selling of $8.9 million with …

Lineage Is Maintained at Neutral by UBS

UBS has reiterated its "Neutral" rating on Lineage. The article headline indicates that this rating has been maintained.

Amneal Pharmaceuticals stock hits 52-week high at 17.86 USD By Investing.com

Amneal Pharmaceuticals Inc. (AMRX) stock reached a new 52-week high of $17.86, trading at $17.87 with a market capitalization of $5.65 billion. This milestone follows a 116.75% increase over the past year, driven by strong financial performance including Q1 2026 EPS of $0.27 and …

MaxLinear (MXL) Earnings Fuel AI Optics Story As Valuation Questions Grow

MaxLinear (MXL) reported a 43% year-over-year revenue increase, driven by infrastructure optics for data centers and AI platforms, leading to a significant 280.47% share price gain over 90 days. Despite this growth and investor enthusiasm for its AI optics story, the stock is considered …

Amneal gains FDA approval for four iohexol products

Amneal Pharmaceuticals received FDA approval for four new iohexol injection presentations, including three 350 mg iodine/mL vial sizes, expanding its generic contrast-agent portfolio. These products, targeting a $706 million U.S. market, are the first generic versions referencing OMNIPAQUE across these approved presentations. Amneal plans …

MaxLinear slumped 16%, extending a two-week slide (MXL:NASDAQ)

MaxLinear (MXL) shares dropped 16% on Thursday, continuing a two-week decline for the semiconductor stock. The drop brings the stock to $74.40, a $14.44 decrease for the session. The company designs communications systems-on-chip for various infrastructure and data center applications, with recent volatility attributed …

MaxLinear Drops 7.3% Amid Sector-Wide Selling

MaxLinear (MXL) shares dropped 7.3% on Thursday due to a broad sell-off across the semiconductor sector, closing at $82.36. The decline was sector-driven rather than company-specific, mirroring losses in other chip stocks like SITM, SMTC, and ALGM. Investors are advised to monitor sector stabilization, …

AAOI vs. MXL: Which AI Data Center Infrastructure Stock Has an Edge?

This article compares Applied Optoelectronics (AAOI) and MaxLinear (MXL), two key suppliers to the AI data center infrastructure market, to determine which stock has greater upside potential. While both companies are experiencing significant growth due to AI demand, MaxLinear appears to have an edge …

Is Amneal Pharmaceuticals (AMRX) Fairly Valued After Its Sharp Rerating?

Amneal Pharmaceuticals (AMRX) has experienced a significant rerating with strong short-term and long-term shareholder returns. While analysts consider it slightly undervalued at $18.25, a Discounted Cash Flow (DCF) model suggests a much higher fair value of $53.36, indicating potential undervaluation. The article highlights strategic …

Stifel Maintains MaxLinear(MXL.US) With Buy Rating, Maintains Target Price $110

Stifel has reiterated its Buy rating for MaxLinear (MXL.US) and maintained its target price at $110. This indicates a continued positive outlook from the firm regarding the semiconductor company's stock performance.

MaxLinear (MXL) Is Up 7.9% After Surging Q1 Optics-Driven Infrastructure Revenue - Has The Bull Case Changed?

MaxLinear (MXL) saw its stock rise 7.9% following strong Q1 2026 earnings, with revenue up 43% year-over-year driven by a 136% increase in infrastructure sales, particularly from optics-driven data center platforms and AI-focused products. This growth strengthens the bull case for MaxLinear's pivot towards …

Amneal schedules July 30 call for second-quarter 2026 results

Previsão SAPR4 — Preço Alvo para 2027

Pineapple Resources Berhad Appoints Douglas Wong Hup Min as Executive Director, Effective June 10, 2026

What's Driving Amneal's 2026 Growth Outlook?

Donear FY26 net profit rises 36% to ₹434.64 crore